Moderna : Un management confiant en ce début d’année
>Un consensus qui nous semble prudent - Nous avions hier Stéphane Bancel, CEO de Moderna, en interview lors du forum ODDO BHF. Cette intervention à la suite de l’approbation de son Vaccin contre la COVID-19 en Europe a été des plus rassurantes. Comme souligné par le management de Moderna, nous croyons que le vaccin à ARNm protègera également contre les différentes mutations actuelles. Pour rappel, le vaccin de Moderna exprime la protéine Spike complète du virus ...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.